Use of sorbitol as pharmaceutical excipient in the present day formulations – issues and challenges for drug absorption and bioavailability

التفاصيل البيبلوغرافية
العنوان: Use of sorbitol as pharmaceutical excipient in the present day formulations – issues and challenges for drug absorption and bioavailability
المؤلفون: Ranjeet Prasad Dash, R. Jayachandra Babu, Nuggehally R. Srinivas
المصدر: Drug Development and Industrial Pharmacy. 45:1421-1429
بيانات النشر: Informa UK Limited, 2019.
سنة النشر: 2019
مصطلحات موضوعية: Drug, Drug Compounding, media_common.quotation_subject, Administration, Oral, Biological Availability, Pharmaceutical Science, Excipient, 02 engineering and technology, Pharmacology, 030226 pharmacology & pharmacy, Excipients, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Pharmacokinetics, Drug Discovery, medicine, Humans, Sorbitol, Theophylline, Cimetidine, Sugar alcohol, media_common, chemistry.chemical_classification, Organic Chemistry, 021001 nanoscience & nanotechnology, Bioavailability, carbohydrates (lipids), chemistry, Gastrointestinal Absorption, Charcoal, Delayed-Action Preparations, 0210 nano-technology, medicine.drug
الوصف: Sorbitol is a popular sugar alcohol which has been used as an excipient in formulations of various drugs. Although from a safety perspective the presence of sorbitol in drug formulations does not raise a concern, reports have emerged and these suggest that sorbitol in drug formulations may alter oral absorption and bioavailability of certain drugs. The focus of this article was to review the published literature of various drugs where pharmacokinetic data has been reported for the drug alone versus drug administered with sorbitol and provide perspectives on the pharmacokinetic findings. Interestingly, for BCS class I drugs such as theophylline, metoprolol, the oral absorption, and bioavailability were generally not affected by sorbitol. However, theophylline oral absorption and bioavailability were decreased when sustained release formulation was used in place of immediate release formulation. For drugs such as risperidone (BCS class II) and lamivudine and ranitidine (BCS class III), the solution formulations showed diminished oral bioavailability in presence of sorbitol, whereas cimetidine and acyclovir (BCS class III), did not show any changes in pharmacokinetic profiles due to sorbitol. Finally, the presence of activated charcoal with sorbitol showed different pharmacokinetic outcome for BCS class I and II drugs.
تدمد: 1520-5762
0363-9045
DOI: 10.1080/03639045.2019.1640722
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ba54ee10d11e1631d3eea22de67eb51
https://doi.org/10.1080/03639045.2019.1640722
رقم الانضمام: edsair.doi.dedup.....3ba54ee10d11e1631d3eea22de67eb51
قاعدة البيانات: OpenAIRE
الوصف
تدمد:15205762
03639045
DOI:10.1080/03639045.2019.1640722